Adaptimmune Therapeutics (ADAPY) AI Stock Analysis

• Market Cap: $10.34M
• Dividend Yield: N/A
• Average Volume (3M): 50.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -53.61%
• EPS Growth: -93.14%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 4,539,686
• 30 Day Avg. Volume: 50,649,310
• PEG Ratio: 0.04
• Price to Book (P/B): 11.47
• Price to Sales (P/S): 0.76
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.05 ▼(-8.00% Downside)

The overall stock score is heavily influenced by the company's weak financial performance and valuation metrics. The technical analysis also suggests a bearish trend, contributing to the low score. The absence of positive earnings call insights or corporate events further limits any potential upside.

Positive Factors

Proprietary TCR Technology

Adaptimmune's proprietary TCR technology offers a competitive edge in developing targeted cancer therapies, potentially leading to successful treatments and partnerships.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management in production, which can support profitability as revenue stabilizes or grows.

Free Cash Flow Growth

Improvement in free cash flow growth suggests better cash management, providing more resources for strategic investments and operational needs.

Negative Factors

Declining Revenue

Significant revenue decline reflects challenges in market demand or product adoption, potentially impacting long-term financial stability.

Negative Profitability

Ongoing negative profitability suggests operational inefficiencies and may hinder the company's ability to sustain growth without restructuring.

Precarious Balance Sheet

A precarious balance sheet with negative equity raises concerns about financial stability and solvency, limiting strategic flexibility.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics is a biotechnology company specializing in the development of T-cell therapy for cancer treatment. The company focuses on harnessing the power of the immune system to create innovative therapies that target specific cancer antigens, particularly in the sectors of oncology and immunotherapy. Adaptimmune's core products include its proprietary SPEAR T-cell therapies, which are designed to treat a variety of cancers, including solid tumors and hematologic malignancies.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of therapies developed in partnership. The company may also earn revenue from clinical trial agreements and grants that support its research and development efforts. Additionally, any successful commercialization of its SPEAR T-cell therapies could lead to significant revenue through product sales, particularly if these therapies gain regulatory approval and are adopted widely in clinical settings.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics is facing significant financial challenges, with declining revenues, negative profitability, and a precarious balance sheet. Despite some improvement in free cash flow growth, the company's financial health remains weak, requiring strategic interventions to stabilize and improve its financial position.

Income Statement

Adaptimmune Therapeutics has experienced significant revenue volatility, with a sharp decline in TTM revenue growth of -63.77%. The company maintains a high gross profit margin of 98.06% in TTM, but this is overshadowed by negative net profit margins and EBIT margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity in TTM, leading to a negative debt-to-equity ratio. The return on equity is also negative, reflecting substantial losses relative to equity. These factors suggest financial instability and potential solvency risks.

Cash Flow

Cash flow analysis shows a significant free cash flow growth of 73.93% in TTM, but the company still faces negative operating cash flow and free cash flow figures. The operating cash flow to net income ratio is negative, indicating cash flow challenges relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.08M	178.03M	60.28M	27.15M	6.15M	3.96M
Gross Profit	61.70M	177.96M	50.42M	-100.58M	-104.94M	-87.61M
EBITDA	-149.75M	-52.66M	-128.20M	-155.59M	-155.68M	-125.81M
Net Income	-169.76M	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M
Balance Sheet
Total Assets	130.63M	245.96M	282.62M	328.92M	469.55M	451.14M
Cash, Cash Equivalents and Short-Term Investments	26.06M	151.60M	146.94M	204.60M	369.58M	368.22M
Total Debt	48.68M	74.21M	25.23M	23.08M	25.47M	23.71M
Total Liabilities	201.59M	234.11M	243.10M	247.04M	263.58M	109.92M
Stockholders Equity	-70.96M	11.85M	39.51M	81.88M	205.96M	341.23M
Cash Flow
Free Cash Flow	-191.71M	-75.93M	-145.76M	-171.51M	1.95M	-56.50M
Operating Cash Flow	-190.03M	-73.21M	-140.88M	-141.77M	10.73M	-53.59M
Investing Cash Flow	1.79M	-58.95M	176.54M	89.14M	75.80M	-278.92M
Financing Cash Flow	1.34M	78.75M	880.00K	12.87M	3.29M	340.05M

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAPY, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.08, and below the 200-day MA of 0.19, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.52 is Neutral, neither overbought nor oversold. The STOCH value of 76.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADAPY.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRSN	56 Neutral	$40.72M	-0.55	―	―	-4.76%	8.09%
XLO	54 Neutral	$38.44M	―	-908.28%	―	588.40%	61.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNTI	47 Neutral	$58.37M	-0.67	-394.62%	―	―	78.60%
LVTX	44 Neutral	$42.75M	-1.54	-101.50%	―	-32.06%	16.38%
ADAPY	40 Underperform	$10.34M	―	-1341.37%	―	-53.61%	-93.14%
BCAB	35 Underperform	$47.54M	―	―	―	-100.00%	32.37%